melatonin has been researched along with Alopecia in 15 studies
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present work aims to formulate nanostructured lipid carriers (NLCs) exhibiting high skin deposition and high inherent antioxidant potential to repurpose the use of melatonin hormone and some antioxidant oils in the treatment of androgenic alopecia (AGA)." | 9.27 | Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils. ( Elkheshen, SA; Geneidi, AS; Hatem, S; Moftah, NH; Nasr, M; Ragai, MH, 2018) |
| "The purpose of the study was to evaluate intermediate adrenal steroid hormones (ISH) in neutered dogs with hair cycle arrest (Alopecia X) during treatment with melatonin, and to see if hair re-growth is associated with sex hormone concentrations within the normal ranges." | 9.11 | Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane. ( Frank, LA; Hnilica, KA; Oliver, JW, 2004) |
| "The strategy in this work was loading Melatonin (MEL), the powerful antioxidant photosensitive molecule, in novel Pickering emulsions (PEs) stabilized by chitosan-dextran sulphate nanoparticles (CS-DS NPs) and enhanced by lecithin, for treatment of androgenic alopecia (AGA)." | 8.31 | Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model. ( Abd-Elmonsif, NM; Elshall, AA; Ghoneim, AM; Osman, R; Shaker, DS, 2023) |
| "The present study aimed to develop vitamin C based nanovesicles (aspasomes) loaded with the antioxidant melatonin, as a novel cosmeceutical to be used for clinical treatment of androgenic alopecia (AGA)." | 7.88 | Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal. ( Elkheshen, SA; Geneidi, AS; Hatem, S; Moftah, NH; Nasr, M; Ragai, MH, 2018) |
| "A total of 11 human studies were identified with evidence of melatonin use in subjects with diagnosed alopecia (2,267 patients; 1,140M)." | 5.41 | Melatonin and the Human Hair Follicle. ( Babadjouni, A; Mesinkovska, N; Phong, C; Raffi, J; Reddy, M; Zhang, R, 2023) |
| "The present work aims to formulate nanostructured lipid carriers (NLCs) exhibiting high skin deposition and high inherent antioxidant potential to repurpose the use of melatonin hormone and some antioxidant oils in the treatment of androgenic alopecia (AGA)." | 5.27 | Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils. ( Elkheshen, SA; Geneidi, AS; Hatem, S; Moftah, NH; Nasr, M; Ragai, MH, 2018) |
| "The purpose of the study was to evaluate intermediate adrenal steroid hormones (ISH) in neutered dogs with hair cycle arrest (Alopecia X) during treatment with melatonin, and to see if hair re-growth is associated with sex hormone concentrations within the normal ranges." | 5.11 | Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane. ( Frank, LA; Hnilica, KA; Oliver, JW, 2004) |
| "The strategy in this work was loading Melatonin (MEL), the powerful antioxidant photosensitive molecule, in novel Pickering emulsions (PEs) stabilized by chitosan-dextran sulphate nanoparticles (CS-DS NPs) and enhanced by lecithin, for treatment of androgenic alopecia (AGA)." | 4.31 | Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model. ( Abd-Elmonsif, NM; Elshall, AA; Ghoneim, AM; Osman, R; Shaker, DS, 2023) |
| "The present study aimed to develop vitamin C based nanovesicles (aspasomes) loaded with the antioxidant melatonin, as a novel cosmeceutical to be used for clinical treatment of androgenic alopecia (AGA)." | 3.88 | Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal. ( Elkheshen, SA; Geneidi, AS; Hatem, S; Moftah, NH; Nasr, M; Ragai, MH, 2018) |
| "Male-pattern baldness (MPB) is a common and highly heritable trait characterized by androgen-dependent, progressive hair loss from the scalp." | 2.55 | Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness. ( Anhalt, T; Becker, T; Chew, EG; Dedoussis, G; Del Rosario, RC; Deloukas, P; Drichel, D; Fier, HL; Galesloot, TE; Hecker, J; Heilmann-Heimbach, S; Heng, XT; Herold, C; Hillmer, AM; Hinds, DA; Hochfeld, LM; Javed, A; Kanoni, S; Kiemeney, LA; Kutalik, Z; Li, R; Martin, NG; Moebus, S; Nöthen, MM; Nothnagel, M; Nyholt, DR; Papanikolaou, G; Paus, R; Pechlivanis, S; Philpott, MP; Prabhakar, S; Richards, JB; Rueedi, R; Spector, TD; Vollenweider, P; Waeber, G, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Verschuuren, MUMY | 1 |
| Schlotter, YM | 1 |
| van Geijlswijk, IM | 1 |
| van der Lugt, JJ | 1 |
| Gehring, R | 1 |
| Babadjouni, A | 1 |
| Reddy, M | 1 |
| Zhang, R | 1 |
| Raffi, J | 1 |
| Phong, C | 1 |
| Mesinkovska, N | 1 |
| Elshall, AA | 1 |
| Ghoneim, AM | 1 |
| Abd-Elmonsif, NM | 1 |
| Osman, R | 1 |
| Shaker, DS | 1 |
| Karabulut, İY | 1 |
| Gokcay, H | 1 |
| Belli, H | 1 |
| Hatem, S | 2 |
| Nasr, M | 2 |
| Moftah, NH | 2 |
| Ragai, MH | 2 |
| Geneidi, AS | 2 |
| Elkheshen, SA | 2 |
| Famenini, S | 1 |
| Goh, C | 1 |
| Heilmann-Heimbach, S | 1 |
| Herold, C | 1 |
| Hochfeld, LM | 1 |
| Hillmer, AM | 1 |
| Nyholt, DR | 1 |
| Hecker, J | 1 |
| Javed, A | 1 |
| Chew, EG | 1 |
| Pechlivanis, S | 1 |
| Drichel, D | 1 |
| Heng, XT | 1 |
| Del Rosario, RC | 1 |
| Fier, HL | 1 |
| Paus, R | 1 |
| Rueedi, R | 1 |
| Galesloot, TE | 1 |
| Moebus, S | 1 |
| Anhalt, T | 1 |
| Prabhakar, S | 1 |
| Li, R | 1 |
| Kanoni, S | 1 |
| Papanikolaou, G | 1 |
| Kutalik, Z | 1 |
| Deloukas, P | 1 |
| Philpott, MP | 1 |
| Waeber, G | 1 |
| Spector, TD | 1 |
| Vollenweider, P | 1 |
| Kiemeney, LA | 1 |
| Dedoussis, G | 1 |
| Richards, JB | 1 |
| Nothnagel, M | 1 |
| Martin, NG | 1 |
| Becker, T | 1 |
| Hinds, DA | 1 |
| Nöthen, MM | 1 |
| Perego, R | 1 |
| Proverbio, D | 1 |
| Roccabianca, P | 1 |
| Spada, E | 1 |
| Fischer, TW | 1 |
| Burmeister, G | 1 |
| Schmidt, HW | 1 |
| Elsner, P | 1 |
| Peres, MF | 1 |
| Zukerman, E | 1 |
| da Cunha Tanuri, F | 1 |
| Moreira, FR | 1 |
| Cipolla-Neto, J | 1 |
| Frank, LA | 2 |
| Hnilica, KA | 1 |
| Oliver, JW | 1 |
| Sladden, MJ | 1 |
| Hutchinson, PE | 1 |
| Diaz, SF | 1 |
| Torres, SM | 1 |
| Nogueira, SA | 1 |
| Gilbert, S | 1 |
| Jessen, CR | 1 |
| Donnell, RL | 1 |
| Kania, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches[NCT00391755] | Phase 4 | 4 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Failure to recruit necessary number of patients.) | ||
| Melatonin for Migraine Prevention (The MMP-study): A Randomized, Double-blind, Cross-over, Placebo-controlled Study of Melatonin in Prophylactic Treatment of Migraine[NCT00849511] | Phase 2 | 48 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| "Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: The BRAiN-M Study"[NCT02344316] | Phase 2 | 31 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study. (NCT02344316)
Timeframe: Weeks 12-16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Melatonin | 11 |
| Placebo | 10 |
eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant. (NCT02344316)
Timeframe: "during the At Home Active Study Period or Weeks 5-16"
| Intervention | Mean Number of Openings (Mean) |
|---|---|
| Melatonin | 39 |
| Placebo | 60 |
Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary. (NCT02344316)
Timeframe: final 4 weeks of treatment
| Intervention | days (Mean) |
|---|---|
| Melatonin | 3.6 |
| Placebo | 4.9 |
Number of minutes to sleep onset as measured by a FitBit. (NCT02344316)
Timeframe: 16 weeks
| Intervention | minutes (Mean) |
|---|---|
| Melatonin | 15.2 |
| Placebo | 17.2 |
2 reviews available for melatonin and Alopecia
| Article | Year |
|---|---|
Melatonin and the Human Hair Follicle.
Topics: Alopecia; Hair; Hair Follicle; Humans; Male; Melatonin; Scalp | 2023 |
Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adipogenesis; Alopecia; Case-Control Studies; Fibroblast Grow | 2017 |
5 trials available for melatonin and Alopecia
| Article | Year |
|---|---|
The efficacy of subcutaneous slow-release melatonin implants in the prevention of canine flank alopecia recurrence is uncertain: A double-blind, randomized, placebo-controlled study.
Topics: Alopecia; Animals; Dog Diseases; Dogs; Double-Blind Method; Melatonin; Skin | 2022 |
Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils.
Topics: Alopecia; Antioxidants; Cosmeceuticals; Drug Carriers; Drug Repositioning; Humans; Lipids; Melatonin | 2018 |
Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial.
Topics: Administration, Topical; Adult; Aged; Alopecia; Double-Blind Method; Female; Hair; Humans; Melatonin | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Alopecia; Androstenedion | 2004 |
8 other studies available for melatonin and Alopecia
| Article | Year |
|---|---|
Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model.
Topics: Alopecia; Animals; Antioxidants; Chitosan; Dextrans; Emulsions; Hair; Lecithins; Melatonin; Minoxidi | 2023 |
Hair Loss Associated with Escitalopram: Do SSRIs Affect Melatonin at the Hair Follicle?
Topics: Alopecia; Citalopram; Hair Follicle; Humans; Melatonin; Selective Serotonin Reuptake Inhibitors | 2021 |
Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal.
Topics: Adolescent; Adult; Alopecia; Animals; Antioxidants; Ascorbic Acid; Drug Carriers; Drug Liberation; H | 2018 |
Evidence for supplemental treatments in androgenetic alopecia.
Topics: Alopecia; Biological Products; Biotin; Caffeine; Female; Humans; Male; Melatonin; Zinc | 2014 |
Color dilution alopecia in a blue Doberman pinscher crossbreed.
Topics: Administration, Oral; Alopecia; Animals; Antioxidants; Dog Diseases; Dogs; Hair; Hair Color; Male; M | 2009 |
Is melatonin useful in alopecia: critical appraisal of a randomized trial?
Topics: Alopecia; Female; Humans; Melatonin; Randomized Controlled Trials as Topic; Research Design; Treatme | 2005 |
The impact of body site, topical melatonin and brushing on hair regrowth after clipping normal Siberian Husky dogs.
Topics: Adjuvants, Immunologic; Administration, Topical; Alopecia; Animals; Dog Diseases; Dogs; Hair; Hair F | 2006 |
Oestrogen receptor evaluation in Pomeranian dogs with hair cycle arrest (alopecia X) on melatonin supplementation.
Topics: Alopecia; Animals; Dietary Supplements; Dog Diseases; Dogs; Female; Hair Follicle; Immunohistochemis | 2006 |